CHest optimisation through antibiotics Infused via Midline or Peripherally inserted central catheter trial: A randomised controlled trial

Not Applicable

Completed

• Conditions: Cystic Fibrosis (CF); non-CF bronchiectasis; bronchiolitis; Public Health - Health service research; Respiratory - Other respiratory disorders / diseases; Human Genetics and Inherited Disorders - Cystic fibrosis; Infection - Other infectious diseases

• Registration Number: ACTRN12618001642279
• Lead Sponsor: Griffith University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-04
• Study Completion: 2020-07-08
• Last Update Posted: 7 December 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 109

Inclusion Criteria

. Respiratory diagnosis of CF or any other respiratory diagnosis including, non-CF bronchiectasis
•0 (>37 weeks) – 18 years of age (17 years + 364 days)
•Referred to the vascular assessment and management service (VAMS) for insertion of a vascular access device to facilitate antibiotic therapy for pulmonary optimisation.
•Infusates deemed compatible with peripheral/midline administration based on assessment of venous infusion extravasation risk
English speaking
Able to provide consent

Exclusion Criteria

Update
• Non-english speaking parent
• Unable to provide consent
• Previous enrolment in current trial
• Thrombosis at level of axillar or sub-clavian that precludes insertion of midline or PICC
- Medical diagnosis of behavioural condition. e.g. autism, ADHD that would make it impossible for a child to co-operate to a level necessary to have the device inserted with anaesthesia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified